- Home
- DSGN vs FENC Comparison
DSGN vs FENC Comparison
Compare DSGN & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- FENC
- Stock Information
- Founded
- DSGN 2017
- FENC 1996
- Country
- DSGN United States
- FENC United States
- Employees
- DSGN N/A
- FENC N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DSGN Health Care
- FENC Health Care
- Exchange
- DSGN Nasdaq
- FENC Nasdaq
- Market Cap
- DSGN 264.4M
- FENC 181.7M
- IPO Year
- DSGN 2021
- FENC 2001
- Fundamental
- Price
- DSGN $6.02
- FENC $4.63
- Analyst Decision
- DSGN Hold
- FENC Strong Buy
- Analyst Count
- DSGN 3
- FENC 2
- Target Price
- DSGN $7.00
- FENC $14.00
- AVG Volume (30 Days)
- DSGN 185.6K
- FENC 79.4K
- Earning Date
- DSGN 11-11-2024
- FENC 11-04-2024
- Dividend Yield
- DSGN N/A
- FENC N/A
- EPS Growth
- DSGN N/A
- FENC N/A
- EPS
- DSGN N/A
- FENC 0.10
- Revenue
- DSGN N/A
- FENC $48,889,000.00
- Revenue This Year
- DSGN N/A
- FENC $162.23
- Revenue Next Year
- DSGN N/A
- FENC $6.86
- P/E Ratio
- DSGN N/A
- FENC $48.43
- Revenue Growth
- DSGN N/A
- FENC 647.88
- 52 Week Low
- DSGN $1.96
- FENC $4.09
- 52 Week High
- DSGN $6.91
- FENC $11.92
- Technical
- Relative Strength Index (RSI)
- DSGN 64.12
- FENC 41.41
- Support Level
- DSGN $4.50
- FENC $4.09
- Resistance Level
- DSGN $5.02
- FENC $4.86
- Average True Range (ATR)
- DSGN 0.35
- FENC 0.21
- MACD
- DSGN 0.08
- FENC 0.03
- Stochastic Oscillator
- DSGN 100.00
- FENC 42.06
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.